Taxol Carboplatin and Erythropoetin
Ovarian Cancer
About this trial
This is an interventional treatment trial for Ovarian Cancer
Eligibility Criteria
Inclusion Criteria: patients with primary ovarian cancer ECOG- 0-2 Age >= 18 no chemotherapy, radiation or immunotherapy in medical history for ovarian cancer adequate bone marrow, liver and kidney reserve: leukocytes ≥ 2.0 x 109/l, platelets ≥ 100 x 109/l, bilirubin <= 2,0 mg%, creatinine <= 1,5 mg% or creatinine clearance ≥ 60 ml/ min, hemoglobin ≥ 9 g/ dl SGOT, SGPT an AP within 3 fold of the reference laboratory's normal range written informed consent Exclusion Criteria: before-existing heart illness, Cardiac infarct within last 6 months Radiotherapy within 4 weeks for study entry Patients in pregnancy or breast feeding (in premenopausal women anticonception has to be assured: intrauterine devices, surgical methods of sterilization, or, in hormone insensitive tumors only, oral, subcutaneous or transvaginal hormonal, non-estrogen containing contraceptives)
Sites / Locations
Arms of the Study
Arm 1
Experimental
Paclitaxel